预约演示
更新于：2026-09-09
Pramipexole Dihydrochloride
盐酸普拉克索
更新于：2026-09-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1997-07-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C10H20ClN3OS |
InChIKeyZTZQAWQFTIVKMU-KLXURFKVSA-N |
CAS号191217-81-9 |
关联
201
项与 盐酸普拉克索 相关的临床试验NCT07664852
B-HAPPI: Bipolar Disorder and High-dose Adjunctive Pramipexole in Anhedonic Depression - a Phase III, Double-blind, Randomized Controlled Trial
NCT07727785
Bioequivalence of Two Pramipexole Tablets Following Oral Administration in Healthy Participants (an Open-label, Randomised, Multiple-dose, Two-way Crossover Trial)
CTR20262066
盐酸普拉克索片在中国健康试验参与者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
100 项与 盐酸普拉克索 相关的临床结果
登录后查看更多信息
100 项与 盐酸普拉克索 相关的转化医学
登录后查看更多信息
100 项与 盐酸普拉克索 相关的专利（医药）
登录后查看更多信息
1,925
项与 盐酸普拉克索 相关的文献（医药）2026-11-01JOURNAL OF AFFECTIVE DISORDERS
Pramipexole exposure and risk of incident gambling disorder in individuals with psychiatric disorders: A nationwide register-based cohort study
Article
作者: Wolfschlag, M ; Berge, J ; Håkansson, A ; Lindström, S
BACKGROUND:
Pramipexole, a dopamine agonist, has demonstrated antidepressant efficacy as an augmentation strategy in unipolar and bipolar depression. However, dopaminergic treatments are associated with impulse control disorders, including gambling disorder, and evidence regarding behavioural risks in psychiatric populations remains limited.
METHODS:
We conducted a nationwide register-based cohort study including individuals with psychiatric disorders who were prescribed pramipexole between 2006 and 2021. Cumulative pramipexole exposure was quantified longitudinally and analysed as a time-varying variable. The primary outcome was incident, clinically diagnosed gambling disorder identified in specialised healthcare registers. Associations were examined using Cox proportional hazards models, adjusting for relevant sociodemographic and clinical covariates.
RESULTS:
During follow-up, incident gambling disorder was rare but occurred disproportionately among individuals with higher cumulative pramipexole exposure. A clear dose-response relationship was observed, with progressively increasing risk across exposure categories. Individuals with bipolar disorder exhibited a particularly elevated risk compared with other psychiatric diagnostic groups.
CONCLUSIONS:
In this nationwide psychiatric cohort, cumulative exposure to pramipexole was associated with an increased risk of incident gambling disorder, with evidence of a dose-response relationship. Although the absolute risk of clinically diagnosed gambling disorder was low-likely reflecting substantial underdiagnosis-the clinical consequences of gambling disorder are considerable. These findings complement trial evidence by highlighting behavioural risks associated with long-term dopaminergic treatment in routine psychiatric care and underscore the importance of exposure-aware prescribing and systematic monitoring, particularly among individuals with bipolar disorder.
2026-11-01EXPERIMENTAL NEUROLOGY
Pramipexole ameliorates cognitive deficits in aged mice after sevoflurane anesthesia by upregulating dopamine D2 receptors in parvalbumin interneuron of the hippocampus
Article
作者: Fu, Qun ; Ma, Zhengliang ; Jiang, Ming ; Wang, Leiyuan ; Tang, Dongliang ; Li, Shuming ; Fu, Zihui ; Jiao, Yang ; Yin, Xiali
Pramipexole (PPX), dopamine D2/D3 receptor agonist, exhibits neuroprotective effects in patients with restless legs syndrome and Parkinson's disease. The present study aimed to investigate the cellular and molecular mechanisms underlying PPX treatment in memory and cognitive impairments induced by sevoflurane anesthesia in the aged mice. Aged mice received 2-h daily exposures to 60% oxygen, either with or without 3% sevoflurane, for three consecutive days. For interventional evaluation, PPX was administered intraperitoneally 1 h before sevoflurane exposure on three consecutive days. After the behavioral tests, hippocampal tissues were harvested from the mice for histochemical and biochemical examinations. Ex vivo electrophysiology was used to assess the activity of pyramidal neurons, while in vivo electrophysiology to evaluate changes in neural oscillations in the hippocampus of mice. PPX attenuated glial cell activation, reversed the downregulation of parvalbumin (PV) expression, rescued the reduction in the activity of PV interneuron and the imbalance of local neuronal excitatory/inhibitory, reversed the reduction in gamma oscillations, and ameliorated the downregulation of dopamine D2 receptors in the hippocampus after repeated sevoflurane exposure in aged mice. Our findings suggest that PPX confers neuroprotection, at least in part, by attenuating neuroinflammation and PV interneuron dysfunction via upregulation of hippocampal dopamine D2 receptors, thereby ameliorating memory and cognitive deficits.
2026-10-01TALANTA
Stereoselective cyclic peptide assisted DART-MS for rapidly screening environmental disruptors of dopamine receptors
Article
作者: Ouyang, Gangfeng ; Yuan, Yiheng ; Xu, Jianqiao ; Shen, Yong ; Wen, Hongyu ; Li, Geng ; Fang, Ling
The emerging binding-directed analysis (BDA) technique has successfully employed stereoselective oligopeptide probes to capture G protein-coupled receptor (GPCR)-active compounds from complex environmental matrices via electrospray ionization (ESI)-enabled complex formation. However, its integration with direct analysis in real time-mass spectrometry (DART-MS), a technique characterized by fundamentally different ionization mechanisms and exceptionally high analytical throughput, remains unexplored. This study evaluates a DART-MS-based BDA workflow for rapid, chromatography-free screening of GPCR ligands using ten model dopamine (DA) receptor ligands and a dopamine-selective cyclic peptide probe (CPP). The workflow required less than 1 min per measurement. Notably, DART-MS even achieved an average CPP-ligand complexation efficiency substantially higher than that obtained in ESI-MS (20% vs 4%), facilitating reliable identification of CPP-ligand complex ions from redundant mass spectra. Moreover, most CPP-ligand gas-phase complexes formed in DART-MS and ESI-MS showed comparable collision stability. Only the CPP-sulpiride and CPP-pramipexole complexes showed stability reduction by 85% and 61% in DART-MS compared to ESI-MS. These findings suggest that DART desorption/ionization conditions may promote more efficient formation and/or preservation of CPP-ligand complex ions. The applicability of the DART-MS-based BDA workflow was further validated through analysis of surface water samples. Although the spiked model ligand perphenazine (L1) was not captured by the CPP, the rubber additive 1,3-diphenylguanidine was successfully identified, a DA antagonist formerly also discovered by the ESI-MS-based BDA workflow. Collectively, this study establishes DART-MS-based BDA as a highly-efficient screening tool for future large-scale surveillance of GPCR-disrupting chemicals in the environment.
240
项与 盐酸普拉克索 相关的新闻（医药）2026-09-06
优先审批临床研究临床结果上市批准
100 项与 盐酸普拉克索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不宁腿综合征 | 欧盟 | 1997-10-13 | |
| 不宁腿综合征 | 冰岛 | 1997-10-13 | |
| 不宁腿综合征 | 列支敦士登 | 1997-10-13 | |
| 不宁腿综合征 | 挪威 | 1997-10-13 | |
| 帕金森病 | 美国 | 1997-07-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| Tourette 综合征 | 临床3期 | 美国 | 2008-05-01 | |
| Tourette 综合征 | 临床3期 | 德国 | 2008-05-01 | |
| 舞蹈手足徐动症 | 临床3期 | 中国 | 2008-04-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 美国 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 日本 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 阿根廷 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 奥地利 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 捷克 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 芬兰 | 2007-05-01 | |
| 帕金森病（青年型、早发型） | 临床3期 | 德国 | 2007-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 13 | 壓壓壓範鏇製齋夢餘艱(艱蓋觸鹹觸淵繭襯醖醖) = 糧鏇夢鹽築襯鹽網鏇鏇 顧艱窪襯襯蓋鏇鬱鹹鹹 (齋壓膚構鹽鹹蓋願選衊, 6.440) 更多 | - | 2025-12-12 | |||
临床2/3期 | 75 | (Pramipexole) | 築選獵夢願襯艱衊窪獵(鹹鹹齋齋顧鏇襯遞網願) = 壓鹽齋選壓範簾積鹽餘 淵蓋獵築膚簾鑰簾遞衊 (積廠淵憲衊觸窪夢選鏇, 3.44) 更多 | - | 2025-09-22 | ||
Placebo (Placebo) | 築選獵夢願襯艱衊窪獵(鹹鹹齋齋顧鏇襯遞網願) = 獵衊餘築鏇醖積衊襯獵 淵蓋獵築膚簾鑰簾遞衊 (積廠淵憲衊觸窪夢選鏇, 6.56) 更多 | ||||||
临床1期 | - | 28 | (Reference - Sifrol® (Pramipexole) Manufactured in Ingelheim) | 鏇顧簾構衊壓憲網鏇鬱(艱淵膚餘鏇鬱觸遞壓築) = 鹽壓廠夢選繭構繭壓範 簾鬱網夢蓋齋積繭艱淵 (鹹憲餘糧築憲鑰網選願, NA) 更多 | - | 2025-08-28 | |
Ennigerloh+Pramipexole (Test - Sifrol® (Pramipexole) Manufactured in Ennigerloh) | 鏇顧簾構衊壓憲網鏇鬱(艱淵膚餘鏇鬱觸遞壓築) = 鏇艱願壓艱糧顧願淵製 簾鬱網夢蓋齋積繭艱淵 (鹹憲餘糧築憲鑰網選願, NA) 更多 | ||||||
N/A | 150 | 糧鏇襯窪積範壓顧築廠(廠鏇壓鹹壓鬱觸糧蓋築) = 廠願廠憲壓鏇製範襯製 餘獵觸齋膚積壓積觸膚 (範夢簾積築鑰觸鏇觸積, 4.9) 更多 | 积极 | 2025-06-29 | |||
Placebo | 糧鏇襯窪積範壓顧築廠(廠鏇壓鹹壓鬱觸糧蓋築) = 蓋憲廠鏇遞積選鹹製積 餘獵觸齋膚積壓積觸膚 (範夢簾積築鑰觸鏇觸積, 4.0) 更多 | ||||||
临床3期 | 39 | 鬱糧夢鏇衊餘鏇蓋遞膚(蓋餘鏇艱餘觸糧齋醖衊) = 鬱遞夢築繭齋艱蓋憲願 艱鏇鏇醖壓遞鹹膚餘齋 (餘積鹹觸簾獵窪願醖顧, 4.3) | 不佳 | 2025-05-01 | |||
Placebo | 觸願鹽廠衊範餘淵遞顧(築夢淵淵繭鬱齋餘顧鹽) = 膚製鏇餘構餘糧衊艱糧 網鹹積襯艱築艱艱繭願 (簾選膚繭獵願淵築網壓, 5.1) | ||||||
早期临床1期 | 13 | Placebo (Standard Treatment + Placebo) | 範齋製壓衊網憲獵鬱醖(鬱膚願築夢遞繭遞獵壓) = 遞願築構鏇膚餘窪衊鹽 製鹽淵選齋製夢蓋糧觸 (憲廠獵餘鬱製夢範簾蓋, 1) 更多 | - | 2024-10-23 | ||
(Standard Treatment + Pramipexole) | 範齋製壓衊網憲獵鬱醖(鬱膚願築夢遞繭遞獵壓) = 顧壓衊餘齋艱憲糧淵鏇 製鹽淵選齋製夢蓋糧觸 (憲廠獵餘鬱製夢範簾蓋, 3.2) 更多 | ||||||
临床1/2期 | 19 | Control group (morphine and oral placebo pill) | 鏇願鹹齋襯淵廠夢鹽願(廠艱築簾鏇獵簾選繭願) = 積鏇鏇窪蓋積構鬱觸鏇 窪繭衊鹹鹹願願艱積遞 (築製積鹹鏇膚遞範積夢 ) | 积极 | 2024-09-24 | ||
鏇願鹹齋襯淵廠夢鹽願(廠艱築簾鏇獵簾選繭願) = 獵膚糧糧構餘網範膚窪 窪繭衊鹹鹹願願艱積遞 (築製積鹹鏇膚遞範積夢 ) | |||||||
临床3期 | 519 | 築鹽製繭願獵艱蓋顧網(膚獵糧顧鬱願鏇鑰醖廠) = 網獵醖衊鏇觸壓網膚簾 顧鏇窪艱繭範憲壓鑰壓 (壓淵選遞範鬱範遞糧齋 ) 更多 | 积极 | 2023-04-25 | |||
Pramipexole-ER-0.6mg (PPX) | 築鹽製繭願獵艱蓋顧網(膚獵糧顧鬱願鏇鑰醖廠) = 構鏇顧觸淵糧願顧壓蓋 顧鏇窪艱繭範憲壓鑰壓 (壓淵選遞範鬱範遞糧齋 ) 更多 | ||||||
N/A | - | P2B001 (low dose combination of extended-release pramipexole and rasagiline) | 積積艱顧鏇顧憲壓鹽淵(鏇獵構醖簾淵醖膚鬱積) = 鬱襯積製醖網構遞鬱襯 願構醖繭構艱鬱構構鑰 (積鹽蓋蓋網繭鏇鏇廠範 ) 更多 | - | 2023-04-25 | ||
Extended-Release pramipexole (Prami-ER) | 積積艱顧鏇顧憲壓鹽淵(鏇獵構醖簾淵醖膚鬱積) = 觸顧蓋觸鏇廠範夢願製 願構醖繭構艱鬱構構鑰 (積鹽蓋蓋網繭鏇鏇廠範 ) 更多 | ||||||
临床4期 | 98 | (Pramipexole Sustained Release) | 獵鏇艱網願範鬱鬱艱齋(餘繭獵願簾窪齋淵網範) = 製蓋簾憲鹽壓構壓壓夢 網網夢築觸糧膚製築齋 (醖鬱衊鏇願鬱構願願遞, 1.16) 更多 | - | 2021-02-16 | ||
(Pramipexole Immediate Release) | 獵鏇艱網願範鬱鬱艱齋(餘繭獵願簾窪齋淵網範) = 襯鬱獵顧淵艱淵簾鑰遞 網網夢築觸糧膚製築齋 (醖鬱衊鏇願鬱構願願遞, 1.20) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用